Welcome to the 2nd Annual Biosimilars India 2010

With an estimated $25 billion of biologics coming off patent imminently, biosimilars present the pharma industry with most lucrative market opportunity for a long time. The pharma, biotechnology, CRO, and CMO organisations who prepare themselves today will reap the enormous biosimilars rewards tomorrow.

CPhI Conferences is delighted to present its 2nd Annual Biosimilars India 2010 conference. This two-day strategic event will provide all the key players within the biosimilars value chain with the opportunity to assess the market, determine the right technical strategy, and drive the development and registration of biosimilars products both here in India and overseas.

Take advantage of this forum to gain critical insights into:

• Evolving regulatory environment
• R&D and process development challenges
• Manufacturing and distribution opportunities
• Driving the registration and commercialisation process
• Leveraging the longer term potential of BioBetters & BioSuperiors

 

What the media says about Biosimilars

“The made in India biosimilars market (domestic plus exports) in 2008 was around $200 million and is expected to reach around $580 million by 2012”
(Source: BioSpectrum)

“An estimated $25 billion worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars”
(Source: Business Insights)

“The worldwide market for biopharmaceutical contract manufacturing reached $2.4 billion in 2007, a 14% increase from prior year”
(Source: Contract Pharma)